Preparation, optimization, and evaluation of Zaltoprofen-loaded microemulsion and microemulsion-based gel for transdermal delivery

Journal of Liposome Research
Ratnesh MishraLokesh Kumar Bhatt

Abstract

Zaltoprofen, a non-steroidal anti-inflammatory drug, has potent inhibitory action against nociceptive responses. However, gastrointestinal ulcer accompanied with anemia due to the bleeding are most cited side effects associated with it. Due to this, administration of Zaltoprofen is not suitable for individuals with gastric ulcer. Thus, there is unmet need to develop an alternative delivery system that will be easy to administer and can avoid ulcerogenic side effects associated with it. Present study was aimed to prepare and evaluate microemulsion (ME) and microemulsion-based gel formulation of Zaltoprofen for transdermal delivery. Pseudo-ternary phase diagrams were utilized to prepare ME formulations. Effect of surfactant and co-surfactant mass ratio on the ME formation and permeation of ME were evaluated and formulation was optimized. Permeation studies were performed using excised pigskin was studied. Efficacy of optimized formulations was evaluated in rat model of inflammation and pain. Composition of optimized formulation was 1% (w/w) Zaltoprofen, 20% (w/w) Capryol 90, 50% (w/w) Smix (2:1, Cremophor RH 40 and Transcutol P). Optimized formulation showed globule size of 22.11 nm, polydispersity index of 0.251 and zeta potenti...Continue Reading

References

Jan 1, 1996·Journal of Pharmaceutical Sciences·T OgisoM Iwaki
Nov 27, 1998·Inflammation Research : Official Journal of the European Histamine Research Society ... [et Al.]·S Kawai
Dec 6, 2000·Advanced Drug Delivery Reviews·M J Lawrence, G D Rees
Apr 1, 1956·Journal of the American Pharmaceutical Association·M N MUTIMERG N CYR
Dec 1, 1962·Proceedings of the Society for Experimental Biology and Medicine·C A WINTERG W NUSS
Apr 8, 2006·International Journal of Pharmaceutics·Huabing ChenXiangliang Yang
Jan 15, 2008·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·M-A BolzingerY Chevalier
Jan 17, 2009·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·M M BadranA Fahr
Apr 22, 2011·Arteriosclerosis, Thrombosis, and Vascular Biology·Emanuela Ricciotti, Garret A FitzGerald
Jul 24, 2012·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Rania M Hathout, Ahmed H Elshafeey
Oct 13, 2012·The Journal of Pharmacy and Pharmacology·Yasmine A GomaaVictor M Meidan
Jun 12, 2013·International Journal of Pharmaceutics·Jong-Suep BaekCheong-Weon Cho

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here